Dillon Cockrell Highlights GU Oncology Abstracts Ahead of ASCO 2025
Dillon Cockrell, Medical Oncologist, GU Cancer Expert at Duke Cancer Center, shared a post on LinkedIn:
“ASCO25 is less than 2 weeks away with continued progress expected as usual in GU oncology.
Here’s a few of the abstracts I’m most looking forward to being presented.
Prostate Cancer
- Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE. MMAI from ArteraAI could optimize ARPI use in high-risk local disease.
- A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (COMRADE). Exploring novel combination therapy in mCRPC.
- 177Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC. Is radioligand therapy a key to unlock IO efficacy?
Kidney Cancer
- Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma. Final CheckMate 214 analysis.
- Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma. Long-term data on pembro’s adjuvant benefit.
Bladder Cancer
- First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab, followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer. Continuing attempts at bladder sparing systemic therapy for MIBC.
- Circulating tumor DNA (ctDNA) in patients with MIBC who received perioperative durvalumab in NIAGARA Using Natera ctDNA to guide personalized therapy MIBC.
Explore the full list of abstracts.
See you in Chicago!”
Matthew Kurian, Assistant professor of Medicine at the University of Kentucky College of Medicine, shared this post, adding:
“If you’re looking for fresh insights from a rising star in GU oncology, don’t miss my friend and colleague Dillon Cockrell from Duke Cancer Institute.
He highlights some of the top GU abstracts to watch at ASCO 2025 — definitely worth a look!”
More posts featuring ASCO2025
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023